Adoptive immunotherapy of cancer with polyclonal, 108-fold hyperexpanded, CD4+ and CD8+T cells

Journal of Translational Medicine

Volumn 2, Issue , 2004, Pages

  Wang, Li Xin ^a   Huang, Wen Xin ^a   Graor, Hallie ^a   Cohen, Peter A ^a   Kim, Julian A ^a   Shu, Suyu ^a   Plautz, Gregory E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 7;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SUSCEPTIBILITY; CELL ISOLATION; CONTROLLED STUDY; DOSE RESPONSE; EFFECTOR CELL; FEMALE; GENE ACTIVATION; IMMUNOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTRACRANIAL TUMOR; LUNG METASTASIS; LYMPH NODE CELL; MOUSE; NONHUMAN; SUBCUTANEOUS TISSUE TUMOR; T LYMPHOCYTE; TUMOR LOCALIZATION;

EID: 18144423563     PISSN: 14795876     EISSN: None     Source Type: Journal    
DOI: 10.1186/1479-5876-2-41     Document Type: Article

References (58)

1. Cohen PA, Peng L, Kjaergaard J, et al.: T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit Rev Immunol 2001, 21:215-248.
2. Dudley ME, Wunderlich JR, Robbins PF, et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
3. Rosenberg SA, Packard BS, Aebersold PM, et al.: Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Eng J Med 1988, 319: 1676-1680.
4. Yee C, Thompson JA, Byrd D, et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A 2002, 99:16168-16173.
5. Plautz GE, Bukowski RM, Novick AC, et al.: T-cell adoptive immunotherapy of metastatic renal cell carcinoma. Urology 1999, 54:617-623.
6. de Visser KE, Kast WM: Effects of TGF-beta on the immune system: implications for cancer immunotherapy. Leukemia 1999, 13:1188-1199.
7. Uyttenhove C, Pilotte L, Theate I, et al.: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003, 9:1269-1274.
8. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP: Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997, 3:483-490.
9. Kammula US, Marincola FM, Rosenberg SA: Real-time quantitative polymerase chain reaction assessment of immune reactivity in melanoma patients after tumor peptide vaccination. J Natl Cancer Inst 2000, 92:1336-1344.
10. Disis ML, Grabstein KH, Sleath PR, Cheever MA: Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin Cancer Res 1999, 5:1289-1297.
11. Lee P, Wang F, Kuniyoshi J, et al.: Effects of Interleukin-12 on the Immune Response to a Multipeptide Vaccine for Resected Metastatic Melanoma. Journal of Clinical Oncology 2001, 19:3836-3847.
12. Butterfield LH, Ribas A, Dissette VB, et al.: Determinant Spreading Associated with Clinical Response in Dendritic Cellbased Immunotherapy for Malignant Melanoma. Clin Cancer Res 2003, 9:998-1008.
13. Pittet MJ, Speiser DE, Valmori D, et al.: Ex vivo analysis of tumor antigen specific CD8+ T cell responses using MHC/peptide tetramers in cancer patients. Int Immunopharmacol 2001, 1:1235-1247.
14. Coulie PG, Karanikas V, Lurquin C, et al.: Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen. Immunol Rev 2002, 188:33-42.
15. Hou S, Hyland L, Ryan KW, Portner A, Doherty PC: Virus-specific CD8+ T-cell memory determined by clonal burst size. Nature 1994, 369:652-654.
16. Barouch DH, Letvin NL: CD8+ cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr Opin Immunol 2001, 13:479-482.
17. Engstrand M, Tournay C, Peyrat MA, et al. i: Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000, 69:2243-2250.
18. Finke JH, Tannenbaum C, Storkus W, et al.: Tumor-induced dysfunction in T lymphocytes: increased sensitivity to apoptosis. Urologe A 2004.
19. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL: T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003, 9:5113-5119.
20. Yoshizawa H, Chang AE, Shu S: Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991, 147: 729-737.
21. McHeyzer-Williams MG, Davis MM: Antigen-specific development of primary and memory T cells in vivo. Science 1995, 268:106-111.
22. Bradley LM, Duncan DD, Tonkonogy S, Swain SL: Characterization of antigen-specific CD4+ effector T cells in vivo: immunization results in a transient population of MEL-14-, CD45RBhelper cells that secrete interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma. J Exp Med 1991, 174:547-559.
23. Mobley JL, Rigby SM, Dailey MO: Regulation of adhesion molecule expression by CD8 T cells in vivo. J Immunol 1994, 153:5443-5452.
24. Kagamu H, Touhalisky JE, Plautz GE, Krauss JC, Shu S: Isolation based on L-selectin expression of immune effector T cells derived from tumor-draining lymph nodes. Cancer Res 1996, 56: 4338-4342.
25. Plautz GE, Touhalisky JE, Shu S: Treatment of murine gliomas by adoptive transfer of ex vivo activated tumor-draining lymph node cells. Cell Immunol 1997, 178:101-107.
26. Seeley BM, Barthel SW, To WC, et al.: Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation. Otolaryngol Head Neck Surg 2001, 124:436-441.
27. Peng L, Kjaergaard J, Plautz GE, et al.: Helper-independent, L-selectinlow CD8+ T cells with broad anti-tumor efficacy are naturally sensitized during tumor progression. J Immunol 2000, 165:5738-5749.
28. Wang LX, Chen BG, Plautz GE: Adoptive immunotherapy of advanced tumors with CD62 L-selectin(low) tumor-sensitized T lymphocytes following ex vivo hyperexpansion. J Immunol 2002, 169: 3314-3320.
29. Inoue M, Plautz GE, Shu S: Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells. Cancer Res 1996, 56:4702-4708.
30. Pannetier C, Cochet M, Darche S, et al.: The sizes of the CDR3 hypervariable regions of the murine T-cell receptor beta chains vary as a function of the recombined germ-line segments. Proc Natl Acad Sci U S A 1993, 90:4319-4323.
31. Plautz GE, Inoue M, Shu S: Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors. Cell Immunol 1996, 171:277-284.
32. Peng L, Kjaergaard J, Plautz GE, et al.: Tumor-induced L-Selectin(high) suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy. J Immunol 2002, 169:4811-4821.
33. Mukai S, Kjaergaard J, Shu S, Plautz GE: Infiltration of tumors by systemically transferred tumor-reactive T lymphocytes is required for antitumor efficacy. Cancer Res 1999, 59: 5245-5249.
34. Janssen O, Sanzenbacher R, Kabelitz D: Regulation of activation-induced cell death of mature T-lymphocyte populations. Cell Tissue Res 2000, 301:85-99.
35. Foulds KE, Zenewicz LA, Shedlock DJ, et al.: Cutting edge: CD4 and CD8 T cells are intrinsically different in their proliferative responses. J Immunol 2002, 168:1528-1532.
36. Peng L, Shu S, Krauss JC: Treatment of subcutaneous tumor with adoptively transferred T cells. Cellular Immunol 1997, 178:24-32.
37. Cohen PA, Peng L, Plautz GE, et al.: CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection. Crit Rev Immunol 2000, 20:17-56.
38. Pantaleo G, Soudeyns H, Demarest JF, et al.: Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci U S A 1997, 94:9848-9853.
39. Klein L, Trautman L, Psarras S, et al.: Visualizing the course of antigen-specific CD8 and CD4 T cell responses to a growing tumor. Eur J Immunol 2003, 33:806-814.
40. Wodarz D, Klenerman P, Nowak MA: Dynamics of cytotoxic T-lymphocyte exhaustion. Proc R Soc Lond B Biol Sci 1998, 265:191-203.
41. Kaech SM, Hemby S, Kersh E, Ahmed R: Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
42. Lee PP, Yee C, Savage PA, et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nature Medicine 1999, 5:677-685.
43. Wang Q, Stanley J, Kudoh S, et al.: T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3 associated kinases are present. J Immunol 1995, 155:1382-1392.
44. Uzzo RG, Clark PE, Rayman P, et al.: Alterations in NFkB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 1999, 91:718-721.
45. Schluns KS, Kieper WC, Jameson SC, Lefrancois L: Interleukin-7 mediates the homeostasis of naive and memory CD8 T cells in vivo. Nat Immunol 2000, 1:426-432.
46. Kaech SM, Tan JT, Wherry EJ, et al.: Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003, 4:1191-1198.
47. Hu HM, Poehlein CH, Urba WJ, Fox BA: Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002, 62:3914-3919.
48. Rosenberg SA: Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-384.
49. Kjaergaard J, Peng L, Cohen PA, et al.: Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol 2001, 167: 6669-6677.
50. Oppmann B, Lesley R, Blom B, et al.: Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
51. Cordoba-Rodriguez R, Frucht DM: IL-23 and IL-27: new members of the growing family of IL-12-related cytokines with important implications for therapeutics. Expert Opin Biol Ther 2003, 3: 715-723.
52. Atkins MB, Robertson MJ, Gordon M, et al.: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997, 3: 409-417.
53. low cells promotes the generation of highly potent CD4 antitumor effector T lymphocytes. J Immunol 1998, 160:3444-3452.
54. Plautz GE, Mukai S, Cohen PA, Shu S: Cross-presentation of tumor antigens to effector T cells is sufficient to mediate effective immunotherapy of established intracranial tumors. J Immunol 2000, 165:3656-3662.
55. Sun JC, Bevan MJ: Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003, 300: 339-342.
56. Shedlock DJ, Shen H: Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 2003, 300: 337-339.
57. Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE: Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy. J Immunol 2004, 172:3462-3468.
58. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL: Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003, 278:1910-1914.